Johnson & Johnson says it is looking to grow within China’s pharmaceuticals industry full-speed ahead and announced plans to new acquisitions in the market.
Reports say J&J’s sales in China last year saw a 10 percent increase from 2012, and the company is now running with its success. J&J CEO Alex Gorsky told reporters that the company now wants to acquire drug and consumer health brands in China to expand current partnerships with Chinese drug makers.
Reports say J&J has placed one of its chairmen in charge of all operations in China to facilitate the company’s direction.
The company added that it is not deterred by recent criticism against Chinese government officials accused of unfairly treating foreign companies. Johnson & Johnson was fined by Chinese competition officials for “monopolistic pricing” of its contact lens operations.
Full content: Fierce Pharma
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Justice Department Moves to End NCAA Transfer Rule
May 30, 2024 by
CPI
Kenya’s Competition Authority Proposes Tougher Regulations on Big Tech
May 30, 2024 by
CPI
KKR Secures EU Antitrust Approval for $24 Billion Acquisition of Telecom Italia’s Fixed-Line Network
May 30, 2024 by
CPI
European Court Sides with Tech Giants in Italian Regulatory Dispute
May 30, 2024 by
CPI
US Steel and Nippon Steel Secure International Approvals for $14.9B Merger
May 30, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI